Novartis submits supplemental NDA with US FDA for Glivec® for treatment of certain GI tumors
22-Oct-2001 -
Novartis announced today that it has submitted a supplementary New Drug Application (sNDA) to the US Food and Drug
Administration (FDA), seeking marketing authorisation for its novel drug Glivec® (imatinib)* for the treatment of patients with unresectable (inoperable)
and/or metastatic malignant ...
chemotherapy
chronic myeloid leukemia
food
+7